Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

9 марта 2018 г. обновлено: GlaxoSmithKline

A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma. All subjects must have a BRAF mutation-positive tumour sample. Subjects who have received up to one prior regimen of chemotherapy in the advanced or metastatic melanoma setting will be enrolled into the study. Subjects with any prior BRAF or MEK inhibitor use will be excluded. Approximately 297 subjects will be enrolled with 2:1 randomization (198 subjects into the GSK1120212 arm and 99 subjects into the chemotherapy arm). The primary endpoint for the statistical analysis will be a comparison of progression free survival for subjects receiving GSK1120212 compared to chemotherapy. Subjects who have progression on chemotherapy will be offered the option to receive GSK1120212.

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

322

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Австралия
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Австралия, 2606
        • GSK Investigational Site
    • New South Wales
      • Port Macquarie, New South Wales, Австралия, 2444
        • GSK Investigational Site
      • Waratah, New South Wales, Австралия, 2300
        • GSK Investigational Site
    • Queensland
      • South Brisbane, Queensland, Австралия, 4101
        • GSK Investigational Site
      • Townsville, Queensland, Австралия, 4810
        • GSK Investigational Site
      • Woolloongabba, Queensland, Австралия, 4102
        • GSK Investigational Site
    • South Australia
      • Kurralta Park, South Australia, Австралия, 5037
        • GSK Investigational Site
      • Woodville, South Australia, Австралия, 5011
        • GSK Investigational Site
    • Victoria
      • Heidelberg, Victoria, Австралия, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Австралия, 3004
        • GSK Investigational Site
  • Австрия
      • Graz, Австрия, 8036
        • GSK Investigational Site
      • Wien, Австрия, 1090
        • GSK Investigational Site
  • Аргентина
      • Ciudad Autonoma de Buenos Aires, Аргентина, C1121ABE
        • GSK Investigational Site
  • Бельгия
      • Brussels, Бельгия, 1200
        • GSK Investigational Site
      • Charleroi, Бельгия, 6000
        • GSK Investigational Site
      • Gent, Бельгия, 9000
        • GSK Investigational Site
      • Jette, Бельгия, 1090
        • GSK Investigational Site
      • Kortrijk, Бельгия, 8500
        • GSK Investigational Site
      • Leuven, Бельгия, 3000
        • GSK Investigational Site
      • Wilrijk, Бельгия, 2610
        • GSK Investigational Site
      • Yvoir, Бельгия, 5530
        • GSK Investigational Site
  • Германия
      • Berlin, Германия, 10117
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, Германия, 69120
        • GSK Investigational Site
      • Mannheim, Baden-Wuerttemberg, Германия, 68167
        • GSK Investigational Site
      • Tuebingen, Baden-Wuerttemberg, Германия, 72076
        • GSK Investigational Site
    • Bayern
      • Muenchen, Bayern, Германия, 80804
        • GSK Investigational Site
      • Wuerzburg, Bayern, Германия, 97080
        • GSK Investigational Site
    • Niedersachsen
      • Buxtehude, Niedersachsen, Германия, 21614
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Essen, Nordrhein-Westfalen, Германия, 45122
        • GSK Investigational Site
    • Sachsen
      • Dresden, Sachsen, Германия, 01307
        • GSK Investigational Site
    • Schleswig-Holstein
      • Luebeck, Schleswig-Holstein, Германия, 23538
        • GSK Investigational Site
  • Греция
      • Athens, Греция, 11527
        • GSK Investigational Site
      • Athens, Греция, 185 47
        • GSK Investigational Site
      • Thessaloniki, Греция, 564 29
        • GSK Investigational Site
  • Италия
    • Lombardia
      • Milano, Lombardia, Италия, 20132
        • GSK Investigational Site
      • Milano, Lombardia, Италия, 20133
        • GSK Investigational Site
      • Milano, Lombardia, Италия, 20141
        • GSK Investigational Site
    • Toscana
      • Pisa, Toscana, Италия, 56126
        • GSK Investigational Site
  • Канада
    • Alberta
      • Calgary, Alberta, Канада, T2N 4N2
        • GSK Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Канада, V5Z 4E6
        • GSK Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Канада, B3H 2Y9
        • GSK Investigational Site
    • Ontario
      • Hamilton, Ontario, Канада, L8V 5C2
        • GSK Investigational Site
      • London, Ontario, Канада, N6A 4L6
        • GSK Investigational Site
      • Oshawa, Ontario, Канада, L1G 2B9
        • GSK Investigational Site
      • Ottawa, Ontario, Канада, K1H 8L6
        • GSK Investigational Site
      • Toronto, Ontario, Канада, M5G 2M9
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Канада, H2L 4M1
        • GSK Investigational Site
      • Montreal, Quebec, Канада, H2W 1S6
        • GSK Investigational Site
  • Новая Зеландия
      • Christchurch, Новая Зеландия, 8011
        • GSK Investigational Site
      • Dunedin, Новая Зеландия, 9016
        • GSK Investigational Site
      • Newtown, Wellington, Новая Зеландия, 6002
        • GSK Investigational Site
  • Норвегия
      • Oslo, Норвегия, 0310
        • GSK Investigational Site
  • Польша
      • Poznan, Польша, 61-866
        • GSK Investigational Site
      • Warszawa, Польша, 02-781
        • GSK Investigational Site
      • Warszawa, Польша, 04-125
        • GSK Investigational Site
  • Российская Федерация
      • Chelyabinsk, Российская Федерация, 454087
        • GSK Investigational Site
      • Magnitogorsk, Российская Федерация, 455001
        • GSK Investigational Site
      • Moscow, Российская Федерация, 115478
        • GSK Investigational Site
      • St. Petersburg, Российская Федерация, 197758
        • GSK Investigational Site
  • Соединенное Королевство
      • Aberdeen, Соединенное Королевство, AB25 2ZN
        • GSK Investigational Site
      • Birmingham, Соединенное Королевство, B15 2TH
        • GSK Investigational Site
      • Chelmsford, Соединенное Королевство, CM1 7ET
        • GSK Investigational Site
      • Leeds, Соединенное Королевство, LS9 7TF
        • GSK Investigational Site
      • London, Соединенное Королевство, SW3 6JJ
        • GSK Investigational Site
      • London, Соединенное Королевство, W1G 6AD
        • GSK Investigational Site
      • Manchester, Соединенное Королевство, M20 4BX
        • GSK Investigational Site
      • Oxford, Соединенное Королевство, OX3 7LJ
        • GSK Investigational Site
      • Southampton, Соединенное Королевство, SO16 6YD
        • GSK Investigational Site
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Соединенное Королевство, CB2 2QQ
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, Соединенное Королевство, HA6 2RN
        • GSK Investigational Site
    • Surrey
      • Sutton, Surrey, Соединенное Королевство, SM2 5PT
        • GSK Investigational Site
  • Соединенные Штаты
    • Arizona
      • Tucson, Arizona, Соединенные Штаты, 85724-5024
        • GSK Investigational Site
    • Florida
      • Fort Myers, Florida, Соединенные Штаты, 33916
        • GSK Investigational Site
    • Georgia
      • Athens, Georgia, Соединенные Штаты, 30607
        • GSK Investigational Site
      • Marietta, Georgia, Соединенные Штаты, 30060
        • GSK Investigational Site
    • Iowa
      • Iowa City, Iowa, Соединенные Штаты, 52242
        • GSK Investigational Site
    • Louisiana
      • Metairie, Louisiana, Соединенные Штаты, 70006
        • GSK Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02114
        • GSK Investigational Site
    • New Jersey
      • Morristown, New Jersey, Соединенные Штаты, 07962-1956
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Соединенные Штаты, 43210
        • GSK Investigational Site
    • South Carolina
      • Columbia, South Carolina, Соединенные Штаты, 29210
        • GSK Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Соединенные Штаты, 37404
        • GSK Investigational Site
      • Memphis, Tennessee, Соединенные Штаты, 38120
        • GSK Investigational Site
      • Nashville, Tennessee, Соединенные Штаты, 37203
        • GSK Investigational Site
  • Украина
      • Dnepropetrovsk, Украина, 49102
        • GSK Investigational Site
      • Kharkiv, Украина, 61070
        • GSK Investigational Site
      • Kyiv, Украина, 03022
        • GSK Investigational Site
      • Kyiv, Украина, 03115
        • GSK Investigational Site
      • Lviv, Украина, 79031
        • GSK Investigational Site
      • Sumy, Украина, 40005
        • GSK Investigational Site
      • Sympheropol, Украина, 95023
        • GSK Investigational Site
      • Ternopil, Украина, 46023
        • GSK Investigational Site
      • Uzhgorod, Украина, 88017
        • GSK Investigational Site
  • Франция
      • Boulogne-Billancourt, Франция, 92100
        • GSK Investigational Site
      • Grenoble, Франция, 38043
        • GSK Investigational Site
      • Montpellier, Франция, 34295
        • GSK Investigational Site
      • Nantes, Франция, 44093
        • GSK Investigational Site
      • Paris Cedex 10, Франция, 75475
        • GSK Investigational Site
      • Pierre-Benite cedex, Франция, 69495
        • GSK Investigational Site
      • Rennes, Франция, 35042
        • GSK Investigational Site
      • Tours, Франция, 37044
        • GSK Investigational Site
      • Villejuif, Франция, 94805
        • GSK Investigational Site
  • Чехия
      • Hradec Kralove, Чехия, 500 05
        • GSK Investigational Site
      • Ostrava, Чехия, 708 52
        • GSK Investigational Site
      • Praha 2, Чехия, 128 08
        • GSK Investigational Site
      • Zlin, Чехия, 76275
        • GSK Investigational Site
  • Швейцария
      • Zurich, Швейцария, 8091
        • GSK Investigational Site
  • Швеция
      • Goteborg, Швеция, SE-413 45
        • GSK Investigational Site
      • Linkoping, Швеция, SE-581 85
        • GSK Investigational Site
      • Lund, Швеция, SE-221 85
        • GSK Investigational Site
      • Stockholm, Швеция, SE-171 76
        • GSK Investigational Site
      • Uppsala, Швеция, SE-751 85
        • GSK Investigational Site

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • ≥18 years of age
  • Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
  • Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
  • Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  • Adequate screening organ function

Exclusion Criteria:

  • Any prior use of BRAF inhibitors or MEK inhibitors.
  • Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
  • History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
  • Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor:

All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization

  • History or evidence of cardiovascular risk including any of the following:

    • QTcB ≥ 480 msec.
    • History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible
    • History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
    • History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
  • History of interstitial lung disease or pneumonitis

  • History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):

    • History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
    • Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
  • Evidence of new optic disc cupping.
  • Intraocular pressure > 21 mm Hg as measured by tonography

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Назначение кроссовера
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: GSK1120212
MEK inhibitor
Лекарство: ГСК1120212
Ингибитор МЕК
Активный компаратор: Chemotherapy
Investigator Choice of DTIC or paclitaxel
Лекарство: Chemotherapy
Investigator Choice of DTIC or paclitaxel
Экспериментальный: Crossover
MEK inhibitor after documented progression on Chemotherapy Arm
Лекарство: ГСК1120212
Ингибитор МЕК

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Progression-free Survival in All Participants
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Overall Survival in All Participants
Временное ограничение: Day 1 until death due to any cause (average of 20.3 months)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
Day 1 until death due to any cause (average of 20.3 months)
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
Временное ограничение: Day 1 until death due to any cause (average of 20.3 months)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. NA indicates data was not available.
Day 1 until death due to any cause (average of 20.3 months)
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of Participants With OR as Assessed by the Investigator and Independent Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of Participants With OR Following Cross-over to Trametinib
Временное ограничение: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
OR is defined as the number of participants with evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib. The evaluation was carried out by the Investigator per RECIST, Version 1.1. Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT. Only participants who received at least one dose of Trametinib were included in this population.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INVA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
Временное ограничение: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INDA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
Временное ограничение: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
PFS Following Cross-over to Trametinib as Assessed by the Investigator
Временное ограничение: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death. PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

GlaxoSmithKline

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

22 ноября 2010 г.

Первичное завершение (Действительный)

26 октября 2011 г.

Завершение исследования (Действительный)

16 декабря 2016 г.

Даты регистрации исследования

Первый отправленный

18 ноября 2010 г.

Впервые представлено, что соответствует критериям контроля качества

18 ноября 2010 г.

Первый опубликованный (Оценивать)

22 ноября 2010 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 апреля 2018 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

9 марта 2018 г.

Последняя проверка

1 января 2018 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 114267

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Клинические исследования ГСК1120212

Искать похожие исследования

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

CROs by country

CROs in Russia

Заболевания

Редкие заболевания

Медикаментозные вмешательства

Пищевые добавки

Спонсор / Соавторы

Места

Подписаться